AbbVie inks $10.9B Apogee buyout to bag eczema prospect

AbbVie has finalized a $10.9 billion acquisition of Apogee Therapeutics, a biotech firm specializing in long-acting drugs for autoimmune conditions. The deal targets Apogee’s pipeline, including a potential eczema treatment, positioning AbbVie to compete with Sanofi’s blockbuster Dupixent. Coverage highlights the strategic move as a major play in the crowded immunology space, with outlets like *The Business Journals*, *BioPharma Dive*, and *WSJ* framing it as a bold expansion for AbbVie’s drug portfolio.

The acquisition underscores AbbVie’s focus on high-value biologics, with reports noting the company’s willingness to deploy significant capital for late-stage assets. Analysts cited in *FirstWord Pharma* and *Fierce Biotech* suggest the deal reflects growing competition in autoimmune therapies, where demand for novel treatments remains strong. Regulatory and integration hurdles are not yet addressed in coverage, though industry observers will scrutinize AbbVie’s ability to accelerate Apogee’s pipeline.

Watch for updates on FDA timelines for Apogee’s lead candidates, particularly its eczema drug, which could reshape the competitive landscape if approved. AbbVie’s next moves—such as restructuring Apogee’s team or pivoting its R&D focus—will also draw attention as the deal closes.